Mitsubishi UFJ Trust & Banking Corp Trims Stock Position in IQVIA Holdings Inc. (NYSE:IQV)

Mitsubishi UFJ Trust & Banking Corp lowered its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 4.5% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 81,783 shares of the medical research company’s stock after selling 3,826 shares during the quarter. Mitsubishi UFJ Trust & Banking Corp’s holdings in IQVIA were worth $16,071,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of the stock. Raymond James Financial Inc. purchased a new stake in IQVIA in the fourth quarter valued at approximately $236,120,000. American Century Companies Inc. boosted its holdings in shares of IQVIA by 396.0% in the 4th quarter. American Century Companies Inc. now owns 1,134,737 shares of the medical research company’s stock valued at $222,987,000 after purchasing an additional 905,960 shares during the last quarter. FMR LLC grew its stake in shares of IQVIA by 38.7% during the 3rd quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock valued at $684,213,000 after buying an additional 804,963 shares during the period. JPMorgan Chase & Co. raised its position in shares of IQVIA by 46.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock worth $437,378,000 after buying an additional 583,396 shares during the period. Finally, Nordea Investment Management AB boosted its holdings in IQVIA by 47.4% in the fourth quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock valued at $277,908,000 after acquiring an additional 452,029 shares during the last quarter. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

IQVIA Trading Down 1.2 %

NYSE IQV opened at $177.27 on Friday. The company’s fifty day moving average price is $193.15 and its two-hundred day moving average price is $206.47. The company has a market capitalization of $31.25 billion, a price-to-earnings ratio of 23.64, a price-to-earnings-growth ratio of 1.99 and a beta of 1.50. IQVIA Holdings Inc. has a 12 month low of $176.03 and a 12 month high of $253.84. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84.

IQVIA (NYSE:IQV) last posted its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. As a group, research analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

IQV has been the subject of several research analyst reports. Royal Bank of Canada restated an “outperform” rating and set a $270.00 price target on shares of IQVIA in a research note on Monday, February 10th. Citigroup dropped their target price on shares of IQVIA from $225.00 to $210.00 and set a “neutral” rating for the company in a research report on Tuesday, March 4th. Stifel Nicolaus reduced their price target on shares of IQVIA from $273.00 to $261.00 and set a “buy” rating on the stock in a research report on Friday, February 7th. Morgan Stanley raised their target price on shares of IQVIA from $245.00 to $250.00 and gave the company an “overweight” rating in a research note on Tuesday, February 11th. Finally, Barclays decreased their price target on shares of IQVIA from $255.00 to $235.00 and set an “overweight” rating for the company in a research report on Monday, February 3rd. Five equities research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $249.05.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.